Successful multi-vessel percutaneous coronary intervention with bivalirudin in a patient with severe hemophilia A: A case report and review of literature

Journal of Invasive Cardiology

Volumn 16, Issue 6, 2004, Pages 330-332

  Arora, Umesh K ^a,c   Dhir, Meeney ^b   Cintron, Guillermo ^a   Strom, Joel A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Acute myocardial infarction; Bivalirudin; Hemophilia; Percutaneous coronary intervention

Indexed keywords

BLOOD CLOTTING FACTOR 8; HIRULOG;

ACUTE HEART INFARCTION; ADULT; ANTICOAGULATION; BLEEDING; CASE REPORT; CONGESTIVE HEART FAILURE; DISEASE COURSE; HEART CATHETERIZATION; HEMOPHILIA A; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; SHORT SURVEY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COMPONENT TRANSFUSION; CORONARY ANGIOGRAPHY; FACTOR VIII; HEMOPHILIA A; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; RADIOGRAPHY, INTERVENTIONAL; RECOMBINANT PROTEINS;

EID: 2642515512     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. Lickfert L, Hagendorff A, Jung W, et al. Acute posterior wall infarct after factor VIII concentrate administration to a patient with severe hemophilia A. Dtsch Med Wochenschr 1998 May 22;123:658-662.
2. Rosendaal FR, Briet E, Stibbe J, et al. hemophilia protects against ischemic heart disease: a study of risk factors. Br J Haematol 199075:525-530.
3. Bolton-Maggs PH and Pasi KJ. Haemophilias A and B. Lancet 2003;361:1801-1809.
4. Alsolaiman MM, Chang K, Arjomand H, et al. Acute left anterior descending artery occlusion in a hemophiliac A patient during recombinant factor VIII infusion: Treatment with coronary angioplasty. Cathet Cardiovasc Interv 200050:468-472.
5. Peerlinck K and Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with hemophilia A and inhibitor. Thromb Haemost 1999;82:1775-1776.
6. Bates SM and Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin. Am J Cardiol 1998;82:12P-18P.
7. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low molecular weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114:489S-510S.
8. Xiao Z and Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low molecular weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-256.
9. Bittl JA, Chaitman B, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: The final reanalysis of the bivalirudin angioplasty study. Am Heart J 2001;142:952-959.
10. Henry TD. Overcoming heparin limitations in high-risk percutaneous coronary intervention: The alternative strategy-replacing heparin with bivalirudin. J Invas Cardiol 2002;14:19B-26B.
11. Weitz JI and Bates SM. Acute coronary syndromes: A focus n thrombin. J Invas Cardiol 2002;14(Suppl B):2B-7B.
12. Lincoff, A.M, Kleiman, NS, Kottke-Merchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the comparison of abciximab complications with hirulog for ischemic events trial (CACHET). Am Heart J 2002;143:847-853.
13. Lincoff AM. Pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade: Results of the REPLACE-1 trial (Abstr). J Am Coll Cardiol 2002;39(Suppl A):16A.
14. Lincoff AM, Bittl JA, Harrington RA, et al. for the REPLACE-2 Investigators. Bivalirudin and provisional GP IIb/IIIa blockade compared with heparin and planned GPIIb/IIIa blockade during percutaneous coronary angioplasty. REPLACE-2 randomized trial. J Am Med Assoc 2003;289:853-863.